Individuals Discontinuing Weight-Loss Jabs Gain Back Weight Far More Rapidly Than Those on Conventional Diets

Fresh analysis reveals that individuals who discontinue blockbuster weight-loss injections like Mounjaro or Wegovy may regain shed pounds at a significantly accelerated pace than those who stop conventional lifestyle plans.

Published data in a leading health publication points out that while overweight individuals can lose substantial amounts of their total mass while using the jabs, the mass comes back at an estimated rate of 0.8 kg per month once they quit.

"Users purchasing such treatments need to be cognizant of the danger of rapid rebound weight gain when the medication ends," stated researcher Dr. Susan Jebb.

That rate of regain implies a return to starting mass within about a year and a half.

Analyzing Therapies

The research, which examined 37 of trials involving thousands of participants, compared the outcomes of the injectable medications with other pills.

Researchers note that individuals who lose weight through dieting usually have a less rapid weight regain—around 100 grams monthly—post-intervention.

The Reason for the Rapid Rebound

Nutrition scientists suggest the way of the injections accounts for the heightened regain.

These medications imitate a body's own chemical called glucagon-like peptide-1, which moderates appetite.

"Long-term administration of the hormone concentrations far above than the body's typical production could lead to the system to generate a reduced amount of its own natural GLP-1, and could lessen responsiveness to its effects," said Dr. Adam Collins, a dietetics expert.

"Discontinuation of this medication means appetite is uncontrolled, making excessive eating a significant risk."

A Lifelong Disease?

The NHS advise the jabs for people with weight-linked medical conditions, alongside recommended diet and exercise modifications.

Many experts contend that, given the significant potential of weight regain, the therapy is often long-term.

This view is reinforced by drug manufacturers, who note that the findings "emphasize the long-term character of obesity," comparing it to managing conditions like high blood pressure.

Patient Experiences

Users who have stopped the medication describe a powerful return of hunger.

"It was like a switch flipping and you're instantly ravenous," said one woman.

The struggle is exacerbated if individuals have not developed lasting lifestyle or habit changes during therapy.

Widespread Interest

Survey data show that millions of people in the UK have tried these injections in the past year, with demand remaining high.

• Use is more common among females than men.
• The middle-aged age group shows the greatest usage rates.
• Many obtain the medications through private prescriptions rather than public health services.

In conclusion, clinicians stress that while GLP-1 drugs are powerful tools for shedding pounds, they are not a magic fix and lasting health benefits likely depends on integrated behavioural support.